

**DISCLOSURE OF TRANSFERS OF VALUE FROM PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS**

Reporting period: 2024

	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier <i>OPTIONAL</i>	Donations and Grants to HCOs	Contribution to costs of Events			Fee for service and consultancy		TOTAL <i>OPTIONAL</i>		
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract			
HCPs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>													
	Maciej, Banach	Lodz	Poland	Doktora Seweryna Sterlinga 27/29/205	PL	N/A	N/A			4.533 EUR	542 EUR	N/A	5.075 EUR	
	Andreas, Charalambous	Limassol	Cyprus	29 Megalou Alexandrou	CY	N/A	N/A			2.295 EUR	108 EUR	N/A	2.403 EUR	
	<b>Aggregate amount attributable to transfers of value to such Recipients</b>						N/A	N/A		1.948 EUR			N/A	1.948 EUR
	<b>Number of Recipients in aggregate disclosure</b>						N/A	N/A		14			N/A	14
<b>% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed</b>						N/A	N/A	0%	100%	0%	0%	N/A	88%	
HCOs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>													
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>													
	<b>Aggregate amount attributable to transfers of value to such Recipients</b>												N/A	0 EUR
	<b>Number of Recipients in aggregate disclosure</b>												N/A	0
	<b>% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed</b>						0%	0%	0%	0%	0%	0%	N/A	0%
POs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>													
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>													
	<b>Aggregate amount attributable to transfers of value to such Recipients</b>												N/A	0 EUR
	<b>Number of Recipients in aggregate disclosure</b>												N/A	0
	<b>% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed</b>						0%	0%	0%	0%	0%	0%	N/A	0%
R&D	<b>AGGREGATE DISCLOSURE</b> Transfers of Value re Research & Development as defined in the EFPIA Code of Practice											1.182.195 EUR		